Introduction
============

Acute heart failure (AHF) is a serious disease associated with high morbidity and mortality.[@b1-tcrm-13-379] When the symptoms of AHF are severe in the patients of intensive care units (ICUs), aggressive medical treatment and organ support are required. Only a few studies have examined the epidemiology of ICU patients with AHF,[@b2-tcrm-13-379],[@b3-tcrm-13-379] although some studies have examined specific aspects of such patients.[@b4-tcrm-13-379],[@b5-tcrm-13-379]

Cadmium is a well-known toxic metal.[@b6-tcrm-13-379] Environmental and occupational exposure to cadmium is associated with several clinical diseases, including renal dysfunction, bone disease, and some cancers.[@b6-tcrm-13-379] The half-life period for cadmium is approximately 10 to 30 years and the absorbed cadmium is eliminated from the body primarily in urine.[@b6-tcrm-13-379] Because the urinary excretion of cadmium correlates well with cadmium accumulation in human bodies, the urinary cadmium levels may serve as an indicator of body cadmium burden.[@b7-tcrm-13-379] However, the correlation between urinary cadmium levels and mortality is uncertain in AHF patients.

In the past 20 years, several scoring systems have been used to evaluate illness severity and predict mortality for critically ill patients, such as the Sequential Organ Failure Assessment (SOFA), the Acute Physiology and Chronic Health Evaluation II (APACHE II), the Simplified Acute Physiology Score, and the Multiple Organ Dysfunction Score.[@b8-tcrm-13-379]--[@b11-tcrm-13-379] However, these scoring systems are complicated and time-consuming in clinical practice, and there may be significant inter-observer variability among the physicians who calculate these scores.[@b12-tcrm-13-379] Moreover, there is still no single variable accurately predicting mortality in patients with AHF.

In this study, we evaluated the association between urinary cadmium levels and outcome of AHF patients and compared these results to the SOFA and APACHE II scoring systems.

Methods
=======

This clinical study complied with the guidelines of the Declaration of Helsinki, and was approved by the Institutional Review Board (IRB) of Chang Gung Memorial Hospital, a tertiary referral center in Taiwan (IRB number: 101-3653C).

Patient information and data collection
---------------------------------------

All participants were at least 18 years old and admitted to the cardiac ICU or medical ICU. The included patients presented fatigue, limitation of physical activity, orthopnea and dyspnea, which were compatible with the typical symptoms of heart failure of the New York Heart Association Functional class III or IV.[@b13-tcrm-13-379] The diagnosis of AHF was based on a detailed taking of their history, the assessment of signs/symptoms of congestion and/or hypoperfusion of organs, and confirmed by appropriate additional studies, including electrocardiography, chest roentgenogram and echocardiography, which were recommended by the guidelines of the American College of Cardiology/American Heart Association and the European Society of Cardiology.[@b14-tcrm-13-379],[@b15-tcrm-13-379] The exclusion criteria were as follows: total urine less than 300 mL/day on admission day 1; duration of ICU stay less than 1 day; duration of hospital stay more than 120 days; presence of end-stage renal disease; readmission to the ICU; history of occupational, residential, or other exposure to cadmium or history of intoxication from other heavy metals. In this study, acute respiratory failure was defined as acute onset of respiratory failure that required mechanical ventilator support. Acute kidney injury (AKI) was defined as serum creatinine (SCr) above 2.0 mg/dL and/or daily urine amount less than 500 mL.

For each patient we collected demographic data, laboratory data, length of stay in the ICU, pre-existing chronic disease, etiology of AHF, clinical condition upon ICU admission, data for scoring predictive indices (at least 12 h before death in non-survivors), and outcome. The blood samples were taken within 24 h after ICU admission. The urine samples were collected during the first 24 h to determine the total amount of urinary cadmium on day 1 (D1UCd) of ICU admission.

This study was approved by the Institutional Review Committee of our hospital and adhered to the principles of the Declaration of Helsinki. Written informed consent was obtained from every study patient.

Clinical scoring systems
------------------------

The APACHE II and SOFA scoring models were used to assess the severity of illness for every enrolled participant. We calculated APACHE II scores as described previously;[@b8-tcrm-13-379] physiological assessments were performed using the highest abnormal physiological values obtained on day 1 of ICU admission. We evaluated SOFA scores as described by Vincent et al;[@b11-tcrm-13-379] the highest abnormal value was recorded for each of the six organ systems on day 1 of ICU admission.

Measurement of urinary cadmium
------------------------------

The urine samples of study patients were collected in cadmium-free bottles. The urinary cadmium levels were measured by the method proposed by Jin et al.[@b16-tcrm-13-379] Briefly, 100 μL of urine and 500 μL of trace-metal-grade distilled 0.8 M HNO3 were added to a 1.5 mL Eppendorf vessel, which was shaken immediately. After overnight storage in a refrigerator, these vessels were permitted to warm to room temperature and whirl-mixed for 5--10 s. Then, the vessels were spun in an Eppendorf centrifuge for 5 min at 11,500 rpm. The clear supernatant samples were obtained after the above procedures and transferred directly to graphite furnace containers. We employed electrothermal atomic absorption spectrometry (SpectrAA-220 Zeeman; Varian, Palo Alto, CA, USA) to determine the cadmium levels in these samples. We confirmed the quality control consistently by internal and external quality control procedures. In addition, we used a certified commercially prepared product (Seronorm Trace Elements; Sero AS, Billingstad, Norway) to evaluate the intra-batch accuracy and ensure inter-batch standardization. The coefficient of variation for measurements of cadmium was ≤5.0%.

Statistical analysis
--------------------

The Kolmogorov-Smirnov test was used to determine the normal distribution for continuous variables. Continuous variables are expressed as means ± standard deviations or medians with interquartile ranges (IQRs), and categorical variables as numbers and percentages. Continuous variables were compared using the Student's *t*-test or Mann--Whitney *U* test, as appropriate. Categorical variables were compared using the chi-squared test or Fisher's exact test. We used the linear regression model to identify factors associated with D1UCd. All potential variables (*P*\<0.05) in a simple linear regression model were entered into a multiple linear regression model with backward stepwise procedures. We used the Cox proportional hazard model to measure all variables and determine their significance for prediction of mortality. The hazard ratios (HRs) and 95% confidence intervals (CIs) for death were obtained with this model. All potential variables (*P*\<0.05) in a univariate model were entered into a multivariate Cox model with forward stepwise procedures. We applied the Hosmer-Lemeshow (HL) test to evaluate the goodness-of-fit of these predictive models.[@b17-tcrm-13-379] We plotted receiver operating characteristic (ROC) curves and calculated the area under curve (AUC) to evaluate the performance of different predictors.[@b18-tcrm-13-379] The SPSS 18.0 for Windows XP (SPSS Inc., Chicago, IL,USA) software package was used in all analyses, and a two-sided *P*-value \<0.05 was considered significant.

Results
=======

Patient characteristics
-----------------------

A total of 153 critically ill patients with AHF (94 males and 59 females) were enrolled in this study ([Table 1](#t1-tcrm-13-379){ref-type="table"}). The mean patient age was 70.1±14.2 years. The median duration of ICU stay was 7.0 days (IQR: 4.0--20.0), and the median duration of hospital stay was 21.0 days (IQR: 13.0--36.5). The median score of APACHE II was 15.0 (IQR: 10.0--20.0) and the median score of SOFA was 5.0 (IQR: 3.0--8.0). The median D1UCd was 0.998 μg/day (IQR: 0.475--2.287) and the mean D1UCd was 2.15±3.86 μg/day. The main three etiologies were ischemic heart disease (64.1%, n=98), rheumatic heart disease (9.2%, n=14), and valvular heart disease (8.5%, n=13). The initial status at ICU admission was as follows: 79 (51.6%) patients had acute respiratory failure requiring mechanical ventilation due to acute pulmonary edema, 54 (35.3%) had cardiogenic shock and received inotropic agents, 47 (30.7%) had acute myocardial infarction (AMI) or unstable angina, and 57 (37.3%) had AKI. The overall mortality rate was 24.8% (n=38). As shown in [Tables 1](#t1-tcrm-13-379){ref-type="table"} and [2](#t2-tcrm-13-379){ref-type="table"}, the baseline characteristics and laboratory parameters of the survivors (n=115) and non-survivors (n=38) were compared. These results indicated that non-survivors had longer ICU stays, higher prevalence of AMI and AKI, higher APACHE II and SOFA scores, higher levels of D1UCd, and higher levels of blood urea nitrogen (BUN) and SCr. More of the survivors were smokers and survivors had higher levels of serum albumin (Alb) and hemoglobin (Hgb).

Determinants of urinary cadmium excretion
-----------------------------------------

As shown in [Table 3](#t3-tcrm-13-379){ref-type="table"}, simple linear regression analysis demonstrated D1UCd was positively related to AKI, but negatively related to the serum levels of Alb and Hgb. Stepwise multiple linear regression analysis indicated that D1UCd was positively related to AKI (Beta ± standard error: 0.807±0.444, *P*=0.046), but negatively related to the serum level of Alb (Beta ± standard error: −1.294±0.421, *P*=0.025).

Cox regression analysis for mortality
-------------------------------------

Univariate Cox regression analysis indicated that AKI, high respiratory rate, high BUN, high APACHE II score, and high D1UCd were potential predictors of mortality. As shown in [Table 4](#t4-tcrm-13-379){ref-type="table"}, we used a multivariate Cox regression analysis with forward stepwise methods to determine the independent effects of these potential predictors. The results indicated that high respiratory rate and high D1UCd were independent predictors of ICU mortality. The HR of mortality for each increment of 1 time/min in respiratory rate was 1.11 (95% CI: 1.03--1.20, *P*=0.004) and the HR of mortality for each increment of 1 μg/day in urinary cadmium was 1.20 (95% CI: 1.09--1.32, *P*\<0.001).

Goodness-of-fit and ROC curves of scoring systems and D1UCd
-----------------------------------------------------------

The HL chi-square test was used to evaluate the goodness-of-fit and the results were obtained as follows: (1) D1UCd (HL chi-square =8.32, 8 degrees of freedom \[*df*\], *P*=0.403); (2) APACHE II (HL chi-square =5.93, 8 *df*, *P*=0.655); (3) SOFA (HL chi-square =3.84, 7 *df*, *P*=0.798). As shown in [Figure 1](#f1-tcrm-13-379){ref-type="fig"}, the ROC curves were plotted for the two scoring models and D1UCd, and AUCs were also calculated. The results demonstrated that D1UCd (AUC =0.84±0.03, 95% CI: 0.78--0.91, *P*\<0.001) had better discriminatory performance than the APACHE II score (AUC =0.70±0.05, 95% CI: 0.60--0.77, *P*\<0.001) or the SOFA score (AUC =0.60±0.06, 95% CI: 0.49--0.70, *P*=0.080).

Discussion
==========

This 6-month observational study demonstrated that the main cause of AHF in these critically ill patients was ischemic heart disease (64.1%), similar to two previous studies of AHF patients (70% and 61%).[@b2-tcrm-13-379],[@b3-tcrm-13-379] The mortality rate was 24.8%, also similar to previous studies of ICU patients with AHF (30% and 27.4%).[@b2-tcrm-13-379],[@b3-tcrm-13-379] Notably, we found that D1UCd was remarkably related to ICU mortality after adjusting for potential variables, including APACHE II and SOFA scores. The HR of mortality for each increment of 1 μg/day in urinary cadmium levels was 1.20. A review of the literature indicates this study is the first to reveal that urinary cadmium level was remarkably correlated with mortality of AHF patients.

There are several scoring models[@b8-tcrm-13-379]--[@b11-tcrm-13-379] which are used to evaluate disease severity and predict the outcome of critically ill patients, including APACHE II and SOFA. Although these two models are widely applied in clinical practice, they are not user-friendly systems. In addition, such models are subject to significant inter-observer differences.[@b19-tcrm-13-379] Therefore, a single, reliable, and unbiased predictor of mortality is needed for critical patients because these patients often require prompt and aggressive treatments. Based on the study results, we found that the D1UCd is a simple predictor of mortality for critically ill AHF patients.

The general population (without occupational exposure to cadmium) has a urinary excretion of cadmium less than 2 μg/day,[@b20-tcrm-13-379] but there are no similar data of urinary cadmium levels in AHF patients, after reviewing the previous reports. In this study, the mean D1UCd of critically ill AHF patients was 2.15±3.86 μg/day, which was higher than that (1.07±1.45 μg/day)[@b21-tcrm-13-379] of the general population in Taiwan. Although the physiological mechanism underlying the connection between elevated cadmium levels in biologic fluids and heart failure is unknown, several studies provide some insight. In rats, the heart muscle cells could be deformed by cadmium poisoning because of the increment of free radicals and lipid peroxidation, based on ultrastructural examination.[@b22-tcrm-13-379] Another rat study indicated that cadmium acted solely as an inhibitor of heart pyruvate-malate-supported mitochondrial respiration, suggesting that disturbances in myocardial metabolism and function may occur following cadmium exposure.[@b23-tcrm-13-379] Furthermore, an epidemiologic study of 12,049 US participants demonstrated that urinary cadmium levels were significantly correlated with self-reported prevalence of heart failure.[@b24-tcrm-13-379] A prospective cohort study of 3,348 adults in the US also revealed a significant association between urine cadmium and increased incidence of heart failure.[@b25-tcrm-13-379] Meanwhile, a study of 4,378 participants in Sweden with a 17-year follow-up period demonstrated that the participants in the fourth quartile of blood cadmium levels had significantly higher incidence of heart failure than those in the first quartile.[@b26-tcrm-13-379] All of these findings suggest that elevated cadmium levels may exacerbate the critical condition and increase hospital mortality in AHF patients. However, further investigations are needed to identify the mechanism and confirm the causal effect.

In general, AUC lower than 0.7 was considered as an indicator of poor performance, and higher than 0.8 as good performance. The analytic results indicated that D1UCd outperformed the APACHE II and SOFA scoring models and had the highest AUC (0.84±0.03, 95% CI: 0.78--0.91). We also used the HL goodness-of-fit test to evaluate the calibration of models. Generally, HL statistics lower than 15 and *P*-values of 0.2 to 0.8 indicate a good fit.[@b27-tcrm-13-379],[@b28-tcrm-13-379] The study results showed D1UCd had a good calibration (HL chi-square =8.32, *P*=0.403). These findings revealed that D1UCd had a high discriminatory power and good calibration as a predictor of mortality for AHF patients, and was better than the established predictive scoring systems. Therefore, D1UCd may serve as a single predictor of mortality for AHF patients. It remains to be demonstrated whether lowering the body cadmium levels of AHF patients by chelation therapy will reduce their disease severity and improve their survival rate.

Patients admitted for AHF often develop exacerbated clinical renal function,[@b29-tcrm-13-379] which is mediated through several mechanisms, including renal hypoperfusion caused by low cardiac output, elevated central venous pressure, activation of renin-angiotensin-aldosterone system, endothelial dysfunction, and others.[@b29-tcrm-13-379] Moreover, some drugs for treating AHF and AMI are also associated with impairment of renal function, especially loop diuretics.[@b29-tcrm-13-379] In addition, hypoalbuminemia is common in patients with AHF,[@b30-tcrm-13-379] which may result from enhanced transcapillary escape rate of Alb from the intravascular to extravascular space, loss of nutrients due to increased hepatic venous congestion, decreased synthesis of Alb by liver and protein-losing enteropathy.[@b30-tcrm-13-379] Furthermore, AKI itself would accelerate protein breakdown, which is attributed to acute disease process, uremic toxins, inflammatory mediators, metabolic acidosis, hormonal imbalance and other factors, resulting in hypoalbuminemia.[@b31-tcrm-13-379] In the current study, we demonstrated D1UCd was positively correlated with AKI, but negatively correlated with serum Alb level in AHF patients. Cadmium exposure has well-known toxic effects on the kidneys[@b16-tcrm-13-379] and severe AHF may induce AKI in critically ill patients, so higher urinary cadmium levels might be observed in this population. Moreover, the increased cadmium levels in biologic fluids may influence the synthesis and metabolism of Alb, based on several in vitro studies. For example, Wan et al[@b32-tcrm-13-379] found lower Alb production in rat hepatocytes treated with cadmium and these perturbations were not alleviated after the cells were returned to cadmium-free medium. Gena et al[@b33-tcrm-13-379] reported that cadmium can lead to albuminuria in a pig proximal tubular cell model by impairing reabsorption and secretion. However, further studies are needed to explore the causal relationships between cadmium, AKI, and serum Alb in patients with AHF.

Cadmium has a long biological half-life (10--30 years) in humans and mainly accumulates in the liver and kidney.[@b6-tcrm-13-379],[@b34-tcrm-13-379] After uptake from the lung or the gastrointestinal tract, cadmium in blood is bound to Alb and high molecular weight proteins and transported to the liver,[@b35-tcrm-13-379] where it is bound to metallothionein. After a few days of cadmium exposure, cadmium-metallothionein compounds appear in the blood.[@b35-tcrm-13-379] Because of the small molecular size, these compounds are efficiently filtered by the glomeruli and reabsorbed by the proximal tubule cells.[@b6-tcrm-13-379],[@b35-tcrm-13-379],[@b36-tcrm-13-379] Then, the absorbed cadmium accumulates in the kidneys for a long time with a low rate of urinary excretion.[@b6-tcrm-13-379] Although cadmium exposure is a risk factor of cardiovascular diseases in humans,[@b25-tcrm-13-379],[@b26-tcrm-13-379] and may disturb myocardial metabolism (suggested by animal studies),[@b22-tcrm-13-379],[@b23-tcrm-13-379] it is uncertain whether the basic metabolism of cadmium would be changed in patients with cardiac diseases, including heart failure. Hence, further studies are needed to elucidate its specific role in AHF patients.

Cigarettes are one of the most prominent sources of cadmium exposure, and are associated with an increased mortality due to cardiovascular diseases.[@b6-tcrm-13-379],[@b37-tcrm-13-379] Cadmium oxide produced during the burning of tobacco has a high bioavailability in humans.[@b38-tcrm-13-379] Approximately 30%--40% of the inhaled cadmium oxide is absorbed into the blood circulatory system.[@b38-tcrm-13-379] Compared with non-smokers, smokers have 4--5 times higher cadmium levels in their blood and 2--3 times higher contents of cadmium in their kidneys.[@b38-tcrm-13-379] Although previous studies demonstrated that smoking was a well-known risk factor of mortality and significantly correlated with blood cadmium level, we observed that survivors were more likely to be smokers than non-survivors (50.4% vs 28.9%, *P*=0.024) in these AHF patients. In addition, we found that D1UCd remained independently associated with increased mortality after adjustment for smoking in this study, which indicated that other causes except smoking may be the sources of cadmium exposure in these study patients. Since patients with history of occupational exposure to cadmium or history of intoxication from other heavy metals were excluded, the source of cadmium is most likely from the exposure in daily life such as contaminated food, drinking water, or passive smoking. Further studies are required to explore whether reducing cadmium exposure reduces the mortality of AHF patients.

There are several limitations of this study. First, although D1UCd was significantly associated with hospital mortality in critical AHF patients, the causal relationship is uncertain. Future investigations are required to clarify the underlying mechanisms. Second, not having serial assessments of B-type natriuretic peptide (BNP) is a limitation because a BNP immunoassay was not available to us at the time of this study. BNP reflects cardiac structure and function and can assist in the diagnosis of AHF. However, whether BNP can predict short-term outcome of AHF remains unclear.[@b39-tcrm-13-379] Third, due to the fact that this study was conducted at a single institution with a heterogeneous group of subjects, the study results may not apply to other hospitals. Hence, a multi-center investigation with more patients is warranted to verify the current findings in the future.

Conclusion
==========

This is the first study to demonstrate that the D1UCd was significantly and independently associated with hospital mortality of critical AHF patients. Notably, the D1UCd has good calibration and discriminatory power, and outperformed the established predictive scoring systems. Moreover, D1UCd is a single variable with minimal inter-observer differences. Therefore, D1UCd should be considered a good predictor of mortality for critical AHF patients. Further investigations are needed to clarify these observations.
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###### 

Baseline characteristics of acute heart failure patients on admission to the ICU (n=153)

  Characteristic                                  Survivor (n=115)    Non-survivor (n=38)   *P*-value
  ----------------------------------------------- ------------------- --------------------- -------------
  Demographics                                                                              
   Age (years)                                    69.7±14.5           71.3±13.1             0.547
   Sex (male)                                     75 (65.2)           19 (50.0)             0.124
   Smoking (yes)                                  58 (50.4)           11 (28.9)             **0.024**
   BMI (kg/m^2^)                                  23.6±4.4            22.8±4.3              0.373
   ICU stay (days)                                6.0 (4.0--13.0)     20.0 (9.5--28.5)      \<**0.001**
   Hospital stay (days)                           19.0 (12.0--35.0)   29.5 (17.0--39.3)     0.243
  Comorbidities                                                                             
   Previous CVD                                   91 (79.1)           28 (73.7)             0.504
   Previous CKD with abnormal SCr                 25 (21.7)           14 (36.8)             0.083
   Previous CPD                                   15 (13.0)           5 (13.2)              0.999
   Hyperlipidemia                                 38 (33.0)           10 (26.3)             0.546
   Diabetes mellitus                              54 (47.0)           16 (42.1)             0.708
   Hypertension                                   73 (66.1)           20 (52.6)             0.255
  Etiology of AHF                                                                           
   Ischemic heart disease                         72 (62.6)           26 (68.4)             0.564
   Rheumatic heart disease                        12 (10.4)           2 (5.3)               0.519
   Valvular heart disease                         9 (7.8)             4 (10.5)              0.737
   Idiopathic DCM                                 6 (5.2)             1 (2.6)               0.682
   COPD-related condition                         4 (3.5)             1 (2.6)               0.999
   Others                                         12 (10.4)           4 (10.5)              0.999
  ICU admission status                                                                      
   ARF due to pulmonary edema, with ventilators   60 (52.2)           19 (50.0)             0.853
   Cardiogenic shock, with inotropic drugs        38 (33.0)           16 (42.1)             0.332
   AMI                                            29 (25.2)           18 (47.4)             **0.015**
   AKI                                            35 (30.4)           22 (57.9)             **0.004**
   Others                                         5 (4.3)             1 (2.6)               0.999
  Predictive indices                                                                        
   APACHE II score                                13.0 (9.0--19.0)    19.0 (13.0--24.0)     **0.010**
   SOFA score                                     5.0 (3.0--7.0)      6.0 (3.8--9.0)        **0.044**
   D1UCd (μg)                                     0.73 (0.39--1.53)   3.42 (1.34--6.75)     \<**0.001**

**Notes:** Data are presented as mean ± standard deviations, numbers (percentages), or medians (interquartile ranges). CVDs included stroke, ischemic heart disease, valvular heart diseases, and peripheral vascular diseases. CKD was defined as persistent abnormal renal function (serum creatinine \>1.4 mg/dL) for at least 6 months. CPDs included asthma, chronic bronchitis, COPD, and lung fibrosis. Hyperlipidemia was diagnosed by a physician and required regular treatments with antilipidemic agent. Diabetes mellitus was diagnosed by a physician and required regular treatments with antihyperglycemic drugs. Hypertension was defined as blood pressure above 140/90 mmHg based on at least two measurements and regular treatment with an antihypertensive drug. Shock was defined as mean arterial pressure less than 60 mmHg. Acute respiratory failure was defined as acute onset of respiratory failure that required ventilator support. AKI was defined as serum creatinine above 2.0 mg/dL and/or daily urine amount less than 500 mL. Bold indicates clinical variables are significant in statistical analysis (*P*\<0.05).

**Abbreviations:** AHF, acute heart failure; AKI, acute kidney injury; AMI, acute myocardial infarction; APACHE, Acute Physiology and Chronic Health Evaluation; ARF, acute respiratory failure; BMI, body mass index; CKD, chronic kidney disease; CPD, chronic pulmonary disease; CVD, cardiovascular disease; D1UCd, day 1 urinary excretion of cadmium; DCM, dilated cardiomyopathy; ICU, intensive care unit; SCr, serum creatinine; SOFA, Sequential Organ Failure Assessment.

###### 

Baseline vital signs and biochemical data of acute heart failure patients on admission to the ICU (n=153)

  Variables                                                           Survivor (n=115)       Non-survivor (n=38)    *P*-value
  ------------------------------------------------------------------- ---------------------- ---------------------- -----------
  Vital signs                                                                                                       
   Glasgow coma scale                                                 13.3±3.3               12.4±3.8               0.204
   Mean arterial pressure                                             87.9±20.0              82.8±15.3              0.115
   Body temperature (°C)                                              36.9±0.9               36.9±1.0               0.806
   Heart rate (beats/min)                                             94.9±22.6              98.8±23.7              0.382
   Respiration rate (times/min)                                       20.5±4.7               22.7±6.4               0.054
  Biochemical data                                                                                                  
   Arterial pH                                                        7.39±0.14              7.38±0.14              0.728
   PaO~2~/FiO~2~ (mmHg)[\*](#tfn3-tcrm-13-379){ref-type="table-fn"}   243.9 (161.8--334.7)   239.8 (182.9--350.8)   0.957
   Alb (g/dL)                                                         3.24±0.50              2.95±0.51              **0.005**
   AST (U/L)                                                          39.0 (22.0--84.0)      44.0 (27.3--225.3)     0.316
   ALT (U/L)                                                          29.0 (15.5--59.0)      29.5 (15.0--56.0)      0.850
   Total bilirubin (mg/dL)                                            0.8 (0.6--1.6)         0.8 (0.5--1.3)         0.832
   BUN (mg/dL)                                                        31.0 (19.0--52.0)      57.5 (28.8--74.8)      **0.002**
   SCr (mg/dL)                                                        1.4 (1.1--2.1)         2.3 (1.3--3.5)         **0.006**
   Hgb (g/dL)                                                         11.9±2.9               10.5±3.2               **0.002**
   WBC (10^3^/μL)                                                     11.2±4.0               10.8±4.4               0.691
   Platelets (10^3^/μL)                                               201.8±88.0             214.4±91.7             0.466
   Cardiac ejection fraction (%)                                      35.0 (26.0--49.0)      37.5 (24.5--45.8)      0.737

**Note:**

PaO~2~/FiO~2~: ratio of arterial oxygen partial pressure to fraction of inspired oxygen. Data are presented as means ± standard deviations or medians (interquartile ranges). Bold indicates clinical variables are significant in statistical analysis (*P*\<0.05).

**Abbreviations:** Alb, albumin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; BUN, blood urea nitrogen; Hgb, hemoglobin; SCr, serum creatinine; WBC, white blood cells; ICU, intensive care unit.

###### 

Determinants of urinary cadmium excretion in acute heart failure patients on day 1 of ICU admission (n=153)

  Variable              Simple linear regression (*r*)   *P*-value   Stepwise multiple linear regression (Beta ± standard error)   *P*-value
  --------------------- -------------------------------- ----------- ------------------------------------------------------------- -----------
  AKI (yes =1, no =0)   0.211                            0.009       0.807±0.444                                                   0.046
  Alb (g/dL)            −0.278                           0.002       −1.294±0.421                                                  0.025
  Hgb (g/dL)            −0.161                           0.050                                                                     

**Abbreviations:** ICU, intensive care unit; AKI, acute kidney injury; Alb, albumin; Hgb, hemoglobin.

###### 

Forward multivariate Cox analysis of risk factors for hospital mortality in acute heart failure patients on day 1 of ICU admission (n=153)

  Variable                                          Hazard ratio (95% CI)   *P*-value
  ------------------------------------------------- ----------------------- -----------
  Respiration rate (each increment of 1 time/min)   1.11 (1.03--1.20)       0.004
  D1UCd (each increment of 1 μg)                    1.20 (1.09--1.32)       \<0.001

**Abbreviations:** ICU, intensive care unit; CI, confidence interval; D1UCd, day 1 urinary excretion of cadmium.
